Cargando…
Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
BACKGROUND: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657518/ https://www.ncbi.nlm.nih.gov/pubmed/38028949 http://dx.doi.org/10.1177/20406223231213251 |